Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Elections Post Observer.
Press releases published on May 27, 2025
Golar LNG Limited Interim results for the period ended March 31, 2025
GlobeNewswire
·
May 27, 2025
Highlights and subsequent events Golar LNG Limited (“Golar” or “the Company”) reports Q1 2025 net income attributable to Golar of $8 million, Adjusted EBITDA1 of $41 million and Total Golar Cash1 of $678 million. Concluded the 20-year charter of FLNG Hilli …
Castellum, Inc. Announces Information Concerning 2025 Annual Stockholders Meeting
GlobeNewswire
·
May 27, 2025
VIENNA, Va., May 27, 2025 (GLOBE NEWSWIRE) -- Castellum, Inc. (NYSE-American: CTM) ("Castellum" or "CTM"), a cybersecurity, electronic warfare, and software engineering services company focused on the federal government, reminds stockholders that its 2025 …
Volatus Aerospace Announces Broad National Expansion of Drone Operating Authorities Across Canada, Unlocking Scalable, High-Value Aerial Operations
GlobeNewswire
·
May 27, 2025
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 27, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT; OTCQX: TAKOF; Frankfurt: A2JEQU) (“Volatus”, or the “Company”), a leading …
Volatus Aerospace annonce une vaste expansion nationale des autorisations d'exploitation de drones à travers le Canada, débloquant ainsi des opérations aériennes évolutives et de grande valeur
GlobeNewswire
·
May 27, 2025
/ NE PAS DISTRIBUER AUX AGENCES DE PRESSE DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNIS / TORONTO, 27 mai 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV : FLT; OTCQX : TAKOF; Francfort : A2JEQU) (« Volatus » ou la « Société »), l'un des principaux …
Progress on share buyback programme
GlobeNewswire
·
May 27, 2025
Progress on share buyback programme ING announced today that, as part of our €2.0 billion share buyback programme announced on 2 May 2025, in total 3,075,000 shares were repurchased during the week of 19 May 2025 up to and including 23 May 2025. The shares …
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
GlobeNewswire
·
May 27, 2025
Exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan Milestone payments from Kowa totaling €3 million expected to be received by Nicox in 2025 …
Nicox annonce jusqu’à 3 millions d’euros de paiements d’étapes de la part de Kowa en 2025, alors que NCX 470 se prépare à entrer en essais cliniques de Phase 3 au Japon
GlobeNewswire
·
May 27, 2025
27 mai 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui que son partenaire exclusif au Japon pour NCX …
Vallourec Announces Share Repurchase Program
GlobeNewswire
·
May 27, 2025
Press release VALLOUREC ANNOUNCES SHARE REPURCHASE PROGRAM Meudon (France), May 27, 2025 – Vallourec, a world leader in premium seamless tubular solutions, announces its intention to repurchase shares. Vallourec intends to execute a buyback in the amount …
VALLOUREC ANNONCE UN PROGRAMME DE RACHAT D’ACTIONS
GlobeNewswire
·
May 27, 2025
Communiqué de presse VALLOUREC ANNONCE UN PROGRAMME DE RACHAT D’ACTIONS Meudon (France), 27 mai, 2025 – Vallourec, leader mondial des solutions tubulaires premium sans soudure, annonce son intention de racheter des actions. Vallourec a l'intention de …
Press Release: Sanofi completes acquisition of DR-0201
GlobeNewswire
·
May 27, 2025
Sanofi completes acquisition of DR-0201 Paris, May 27, 2025. Sanofi announces the completion of its acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a private clinical-stage biopharmaceutical company. The acquisition …
Communiqué de presse : Sanofi finalise l’acquisition du DR-0201
GlobeNewswire
·
May 27, 2025
Sanofi finalise l’acquisition du DR-0201 Paris, le 27 mars 2025. Sanofi annonce la finalisation de l’acquisition du DR-0201, un anticorps bispécifique ciblé qui engage les cellules myéloïdes, à Dren Bio, Inc., société biopharmaceutique privée au stade …